Introduction The goal of organ dysfunction Phase I trials is to characterize the safety and
pharmacokinetics of novel agents in cancer patients with liver or kidney dysfunction, but the …

Despite the growing utilization of targeted, immunotherapeutic, and personalized
approaches in cancer, most patients receive conventional cytotoxic chemotherapy as part of …

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of
oxaliplatin 130 mg/m 2 preceded by escalating doses of docetaxel 60 mg/m 2 (75, 90, 100 …

Métodos: se realizó una búsqueda en PubMed de toda la bibliografía publicada hasta julio
de 2011 sobre dosificación de citostáticos en pacientes con función hepática alterada. Se …

It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …

In the past, patients with cancer, who also have hepatic or renal dysfunction, have carried a
triple burden. Not only have they suffered from cancer and organ dysfunction, but until …

Oxaliplatin, a second-generation platinum analog, has evolved as one of the most important
therapeutic agents in the treatment of both metastatic colorectal cancer and stage II/III colon …

The complexity of cancer chemotherapy requires pharmacists be familiar with the
complicated regimens and highly toxic agents used. This column reviews various issues …

Despite the severe adverse effects, toxicity and limited efficacy due to the development of
multidrug resistance (MDR), chemotherapy is still the treatment of choice for most of the …

БЕЛЯЕВ АЛЕКСЕЙ МИХАЙЛОВИЧ 1, ЛЕОНТЬЕВ ОЛЕГ ВАЛЕНТИНОВИЧ 2, РОГАЧЕВ
МИХАИЛ ВАСИЛЬЕВИЧ 1, КИРЕЕВА ГАЛИНА СЕРГЕЕВНА 1, ГАФТОН ГЕОРГИЙ …